



Financial Tear Sheet

Corporate Profile

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).

AVEO Oncology
Investor Relations
Phone: 617-588-1960
E-mail:
ir@aveooncology.com

Stock Performance

AVEO (COMMON STOCK)

Exchange	NASDAQ (US Dollar)
Financial Status Indicator	D
Price	\$0.75
Change (%)	▼ 0.04 (5.06%)
Volume	455,619
52 Week Low	\$0.50
Market Cap	\$82,661,847
Rolling EPS	-0.38
PE Ratio	N/A
Shares Outstanding	110,362,946

Data as of 05/26/17 4:00 p.m. ET



Recent Headlines

05/19/17
AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma

05/16/17
AVEO Announces Appointment of Matthew Dallas as Chief Financial Officer

05/15/17
AVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer

Events

There are currently no events scheduled.

SEC Filings

FILING DATE FORM

05/17/17	DEFA14A
05/17/17	8-K
05/04/17	8-K
05/04/17	10-Q

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed